{"id":"c15baeb3-9b4e-5be1-a207-93592321feec","stable_key":"f812c44f-d0fd-5f01-ba2c-748c0794fcfb:coumarin-leg-positive","predicate":"reduces_in_trial","statement":"Leg edema declined from 25% to 17% above normal in the 1993 trial (P<0.001).","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"13800012-20dc-5f9a-9750-bd3156af60f4","mechanism_event_label":"The same trial reported less leg swelling.","subject":{"id":"9fd9b93a-fdfd-5e09-92d3-0495bff41391","slug":"coumarin","display_name":"Coumarin","entity_type_key":"small_molecule"},"object":{"id":"7688127f-a09d-527c-be26-f3803e65a372","slug":"human-lymphedema-leg-volume","display_name":"Leg volume in human lymphedema","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"13800012-20dc-5f9a-9750-bd3156af60f4","stable_key":"f812c44f-d0fd-5f01-ba2c-748c0794fcfb:coumarin-leg-positive-event","event_type":"observed_intervention","label":"The same trial reported less leg swelling.","description":"Leg edema declined from 25% to 17% above normal in the 1993 trial (P<0.001).","status":"provisional","compartment":null,"participants":[{"entity":{"id":"9fd9b93a-fdfd-5e09-92d3-0495bff41391","slug":"coumarin","display_name":"Coumarin","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"7688127f-a09d-527c-be26-f3803e65a372","slug":"human-lymphedema-leg-volume","display_name":"Leg volume in human lymphedema","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/coumarin-research/8377779.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"d4b9a301f1334d388b1469a12453ee1af75bcb87f52277dbfac03bcdb045c9ad\", \"start_char\": 0, \"end_char\": 1907, \"text_sha256\": \"d4b9a301f1334d388b1469a12453ee1af75bcb87f52277dbfac03bcdb045c9ad\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized double-blind placebo-controlled crossover trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Coumarin 400 mg/day and placebo, six months each","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Small older mixed-population trial; positive arm finding was not reproduced in the larger subsequent study.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Coumarin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"coumarin","display_name":"Coumarin","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The same trial reported less leg swelling.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[coumarin-p8377779] Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. (1993). https://pubmed.ncbi.nlm.nih.gov/8377779/ DOI: 10.1056/nejm199310143291604","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"31 postmastectomy arm and 21 other-cause leg lymphedema patients","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"ff030530-022c-5a7a-8b82-d640e2f2ab45","evidence_kind":"source_excerpt","locator":"Lines 748-759","start_line":748,"end_line":759,"excerpt":"### coumarin-leg-positive\nLeg edema declined from 25% to 17% above normal in the 1993 trial (P<0.001).\nCondition category: normal\nnutrient_topic: Coumarin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The same trial reported less leg swelling.\norganism: Human\ntissue_or_cell_type: 31 postmastectomy arm and 21 other-cause leg lymphedema patients\nexperimental_model: Randomized double-blind placebo-controlled crossover trial\nlimitations: Small older mixed-population trial; positive arm finding was not reproduced in the larger subsequent study.\nexposure: Coumarin 400 mg/day and placebo, six months each\nevidence_span: {\"source_cache\": \"artifacts/coumarin-research/8377779.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"d4b9a301f1334d388b1469a12453ee1af75bcb87f52277dbfac03bcdb045c9ad\", \"start_char\": 0, \"end_char\": 1907, \"text_sha256\": \"d4b9a301f1334d388b1469a12453ee1af75bcb87f52277dbfac03bcdb045c9ad\"}\n[coumarin-p8377779] Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. (1993). https://pubmed.ncbi.nlm.nih.gov/8377779/ DOI: 10.1056/nejm199310143291604","model_system":"Randomized double-blind placebo-controlled crossover trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [coumarin-p8377779] Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. (1993). https://pubmed.ncbi.nlm.nih.gov/8377779/ DOI: 10.1056/nejm199310143291604","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"30e0bbf1-757c-5baf-9102-e81bdd4382f0","stable_key":"import-f812c44f-d0fd-5f01-ba2c-748c0794fcfb","title":"Coumarin: metabolism, signaling and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"069009019d00c903f4dc54e3793d189f4a61fb17b4803dbe73e73a677dfd0910","revision_id":"6596e0b7-7c3e-523a-a79a-aefb725d7d4c","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}